Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.84
SCMP's Cash-to-Debt is ranked lower than
69% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. SCMP: 0.84 )
Ranked among companies with meaningful Cash-to-Debt only.
SCMP' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43  Med: 5.96 Max: No Debt
Current: 0.84
Equity-to-Asset 0.33
SCMP's Equity-to-Asset is ranked lower than
87% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. SCMP: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
SCMP' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.21  Med: 0.45 Max: 0.82
Current: 0.33
-0.21
0.82
Interest Coverage 3.20
SCMP's Interest Coverage is ranked lower than
90% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. SCMP: 3.20 )
Ranked among companies with meaningful Interest Coverage only.
SCMP' s Interest Coverage Range Over the Past 10 Years
Min: 2.27  Med: 12.21 Max: No Debt
Current: 3.2
Piotroski F-Score: 6
Altman Z-Score: 2.33
Beneish M-Score: -2.20
WACC vs ROIC
8.59%
41.55%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 27.28
SCMP's Operating Margin % is ranked higher than
85% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. SCMP: 27.28 )
Ranked among companies with meaningful Operating Margin % only.
SCMP' s Operating Margin % Range Over the Past 10 Years
Min: -32.3  Med: 17.01 Max: 29.02
Current: 27.28
-32.3
29.02
Net Margin % 11.36
SCMP's Net Margin % is ranked higher than
57% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. SCMP: 11.36 )
Ranked among companies with meaningful Net Margin % only.
SCMP' s Net Margin % Range Over the Past 10 Years
Min: -31.6  Med: 7.94 Max: 22.25
Current: 11.36
-31.6
22.25
ROE % 19.11
SCMP's ROE % is ranked higher than
73% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. SCMP: 19.11 )
Ranked among companies with meaningful ROE % only.
SCMP' s ROE % Range Over the Past 10 Years
Min: -37.45  Med: 14.17 Max: 39.55
Current: 19.11
-37.45
39.55
ROA % 5.60
SCMP's ROA % is ranked higher than
52% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. SCMP: 5.60 )
Ranked among companies with meaningful ROA % only.
SCMP' s ROA % Range Over the Past 10 Years
Min: -11.28  Med: 4.54 Max: 19.13
Current: 5.6
-11.28
19.13
ROC (Joel Greenblatt) % 70.30
SCMP's ROC (Joel Greenblatt) % is ranked higher than
82% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. SCMP: 70.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SCMP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -138.06  Med: 82.98 Max: 529.23
Current: 70.3
-138.06
529.23
3-Year Revenue Growth Rate 35.70
SCMP's 3-Year Revenue Growth Rate is ranked higher than
92% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. SCMP: 35.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SCMP' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.2  Med: 22.7 Max: 128.6
Current: 35.7
-21.2
128.6
3-Year EBITDA Growth Rate 78.50
SCMP's 3-Year EBITDA Growth Rate is ranked higher than
96% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. SCMP: 78.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SCMP' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -19.8  Med: 67.8 Max: 206.8
Current: 78.5
-19.8
206.8
3-Year EPS without NRI Growth Rate 37.90
SCMP's 3-Year EPS without NRI Growth Rate is ranked higher than
85% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. SCMP: 37.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SCMP' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -56.3  Med: 2.9 Max: 82.5
Current: 37.9
-56.3
82.5
GuruFocus has detected 4 Warning Signs with Sucampo Pharmaceuticals Inc $SCMP.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» SCMP's 30-Y Financials

Financials (Next Earnings Date: 2017-08-03 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

SCMP Guru Trades in Q2 2016

Chuck Royce 367,516 sh (+2005.02%)
Jim Simons 1,107,700 sh (+34.15%)
Joel Greenblatt Sold Out
Paul Tudor Jones 18,000 sh (-58.95%)
» More
Q3 2016

SCMP Guru Trades in Q3 2016

Steven Cohen 171,600 sh (New)
Chuck Royce 556,313 sh (+51.37%)
Jim Simons 1,353,000 sh (+22.14%)
Paul Tudor Jones Sold Out
» More
Q4 2016

SCMP Guru Trades in Q4 2016

Leon Cooperman 50,000 sh (New)
Paul Tudor Jones 67,811 sh (New)
Joel Greenblatt 55,508 sh (New)
Chuck Royce 782,023 sh (+40.57%)
Jim Simons 1,459,800 sh (+7.89%)
Steven Cohen 133,100 sh (-22.44%)
» More
Q1 2017

SCMP Guru Trades in Q1 2017

Joel Greenblatt 219,916 sh (+296.19%)
Chuck Royce 974,023 sh (+24.55%)
Steven Cohen Sold Out
Leon Cooperman Sold Out
Paul Tudor Jones 67,771 sh (-0.06%)
Jim Simons 1,111,400 sh (-23.87%)
» More
» Details

Insider Trades

Latest Guru Trades with SCMP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:SCLN, NAS:TLGT, NAS:ACET, NAS:KPTI, OTCPK:APHQF, NAS:FLXN, NAS:LBIO, NAS:ADMS, NAS:TOCA, NAS:AQXP, NAS:DEPO, OTCPK:ACBFF, NAS:RIGL, NAS:TTPH, NAS:COLL, NAS:ZYNE, NAS:SNDX, NYSE:LCI, NAS:HRTX, OTCPK:OGRMF » details
Traded in other countries:R3A.Germany,
Headquarter Location:USA
Sucampo Pharmaceuticals Inc is a biopharmaceutical company focused on research and development of proprietary drugs to treat gastrointestinal, ophthalmic, autoimmune, and oncology-based inflammatory disorders.

Sucampo Pharmaceuticals Inc was incorporated on 05 December 1996. The Company is a biopharmaceutical company engaged in research, discovery, development and commercialization of proprietary drugs based on ion channel activators known as prostones. The Company is engaged in developing and/or commercializing prostone-based drugs to treat gastrointestinal, ophthalmic, neurologic, and oncology-based inflammatory disorders, and also considering other potential therapeutic applications of its drug technologies. It generates revenue primarily from product royalties, development milestone payments, clinical development activities and product sales. The Company seeks additional regulatory approvals and additional indications for AMITIZA (lubiprostone), RESCULA (unoprostone isopropyl) and other compounds. Its operations are conducted through subsidiaries based in Japan, the United States, Switzerland, the United Kingdom and Luxembourg. Its reportable geographic segments are Asia, the Americas and Europe. The Company has over 525 active issued patents based on its proprietary prostone technology. It holds all commercialization rights for unoprostone isopropyl except for Japan, Korea, Taiwan and the People's Republic of China.

Top Ranked Articles about Sucampo Pharmaceuticals Inc

Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of America Merrill Lynch 2017 Health Care Conference
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank 42nd Annual Health Care Conference
Sucampo Announces First Quarter 2017 Earnings Call
New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1
Sucampo Acquires Vtesse Inc.
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 16th Annual Needham Healthcare Conference

ROCKVILLE, Md., March 28, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th at 12:10 PM ET.
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator. The presentation will be webcast live and may be accessed from the Event Calendar page of Sucampo's website at http://www.sucampo.com/investors/events-presentations/. A replay of the webcast will also be available on the Company's website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast. About Sucampo Pharmaceuticals, Inc. Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a pipeline of product candidates in clinical development. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland. For more information, please visit www.sucampo.com. The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG. Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals). Twitter  LinkedIn
Contact:
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
[email protected]

Read more...
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Oppenheimer 27th Annual Healthcare Conference

ROCKVILLE, Md., March 15, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the Oppenheimer 27th Annual Healthcare Conference.  Sucampo’s presentation will occur on Tuesday, March 21, 2017 at 3:20 PM Eastern Time.
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator. The presentation will be webcast live and may be accessed from the Event Calendar page of Sucampo's website at http://www.sucampo.com/investors/events-presentations/. A replay of the webcast will also be available on the Company's website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast. About Sucampo Pharmaceuticals, Inc. Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a pipeline of product candidates in clinical development. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the U.K. For more information, please visit www.sucampo.com. The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG. Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals). Twitter  LinkedIn
Contact:
Sucampo Pharmaceuticals, Inc.
Silvia Taylor
Senior Vice President, Investor Relations and Corporate Affairs
1-240-223-3718
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 16.53
SCMP's PE Ratio is ranked higher than
55% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. SCMP: 16.53 )
Ranked among companies with meaningful PE Ratio only.
SCMP' s PE Ratio Range Over the Past 10 Years
Min: 5.52  Med: 27.06 Max: 105.44
Current: 16.53
5.52
105.44
Forward PE Ratio 9.75
SCMP's Forward PE Ratio is ranked higher than
86% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. SCMP: 9.75 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 16.53
SCMP's PE Ratio without NRI is ranked higher than
54% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.85 vs. SCMP: 16.53 )
Ranked among companies with meaningful PE Ratio without NRI only.
SCMP' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.52  Med: 27.06 Max: 105.44
Current: 16.53
5.52
105.44
Price-to-Owner-Earnings 12.25
SCMP's Price-to-Owner-Earnings is ranked higher than
73% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. SCMP: 12.25 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SCMP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 0.43  Med: 33.37 Max: 2344
Current: 12.25
0.43
2344
PB Ratio 2.73
SCMP's PB Ratio is ranked higher than
50% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. SCMP: 2.73 )
Ranked among companies with meaningful PB Ratio only.
SCMP' s PB Ratio Range Over the Past 10 Years
Min: 0.97  Med: 4.57 Max: 11.83
Current: 2.73
0.97
11.83
PS Ratio 2.02
SCMP's PS Ratio is ranked higher than
62% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. SCMP: 2.02 )
Ranked among companies with meaningful PS Ratio only.
SCMP' s PS Ratio Range Over the Past 10 Years
Min: 1.2  Med: 3.07 Max: 9.7
Current: 2.02
1.2
9.7
Price-to-Free-Cash-Flow 27.33
SCMP's Price-to-Free-Cash-Flow is ranked lower than
79% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. SCMP: 27.33 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SCMP' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.67  Med: 28 Max: 326.79
Current: 27.33
3.67
326.79
Price-to-Operating-Cash-Flow 26.08
SCMP's Price-to-Operating-Cash-Flow is ranked lower than
85% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. SCMP: 26.08 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SCMP' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.62  Med: 27.58 Max: 160.85
Current: 26.08
3.62
160.85
EV-to-EBIT 10.46
SCMP's EV-to-EBIT is ranked higher than
66% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. SCMP: 10.46 )
Ranked among companies with meaningful EV-to-EBIT only.
SCMP' s EV-to-EBIT Range Over the Past 10 Years
Min: -2724.9  Med: 12.9 Max: 51.3
Current: 10.46
-2724.9
51.3
EV-to-EBITDA 5.98
SCMP's EV-to-EBITDA is ranked higher than
90% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. SCMP: 5.98 )
Ranked among companies with meaningful EV-to-EBITDA only.
SCMP' s EV-to-EBITDA Range Over the Past 10 Years
Min: -746  Med: 8.4 Max: 193.6
Current: 5.98
-746
193.6
Shiller PE Ratio 38.77
SCMP's Shiller PE Ratio is ranked higher than
52% of the 161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.67 vs. SCMP: 38.77 )
Ranked among companies with meaningful Shiller PE Ratio only.
SCMP' s Shiller PE Ratio Range Over the Past 10 Years
Min: 36.35  Med: 53.66 Max: 2109
Current: 38.77
36.35
2109
Current Ratio 9.26
SCMP's Current Ratio is ranked higher than
89% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. SCMP: 9.26 )
Ranked among companies with meaningful Current Ratio only.
SCMP' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.65 Max: 9.5
Current: 9.26
1.27
9.5
Quick Ratio 8.60
SCMP's Quick Ratio is ranked higher than
89% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. SCMP: 8.60 )
Ranked among companies with meaningful Quick Ratio only.
SCMP' s Quick Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.6 Max: 9.21
Current: 8.6
1.27
9.21
Days Inventory 122.45
SCMP's Days Inventory is ranked lower than
53% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. SCMP: 122.45 )
Ranked among companies with meaningful Days Inventory only.
SCMP' s Days Inventory Range Over the Past 10 Years
Min: 2.34  Med: 69.48 Max: 164.56
Current: 122.45
2.34
164.56
Days Sales Outstanding 31.35
SCMP's Days Sales Outstanding is ranked higher than
56% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. SCMP: 31.35 )
Ranked among companies with meaningful Days Sales Outstanding only.
SCMP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.75  Med: 19.46 Max: 68.22
Current: 31.35
1.75
68.22
Days Payable 42.02
SCMP's Days Payable is ranked lower than
74% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. SCMP: 42.02 )
Ranked among companies with meaningful Days Payable only.
SCMP' s Days Payable Range Over the Past 10 Years
Min: 9.38  Med: 92.95 Max: 662.06
Current: 42.02
9.38
662.06

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.30
SCMP's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. SCMP: -2.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SCMP' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -9.6  Med: -0.65 Max: 0
Current: -2.3
-9.6
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.81
SCMP's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
54% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.56 vs. SCMP: 1.81 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SCMP' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.15  Med: 3.41 Max: 230
Current: 1.81
0.15
230
Price-to-Median-PS-Value 0.66
SCMP's Price-to-Median-PS-Value is ranked higher than
86% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. SCMP: 0.66 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SCMP' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.7  Med: 1.04 Max: 2.41
Current: 0.66
0.7
2.41
Earnings Yield (Greenblatt) % 9.56
SCMP's Earnings Yield (Greenblatt) % is ranked higher than
75% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. SCMP: 9.56 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SCMP' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2  Med: 6.3 Max: 125.2
Current: 9.56
2
125.2

More Statistics

Revenue (TTM) (Mil) $239.1
EPS (TTM) $ 0.62
Beta1.02
Short Percentage of Float25.99%
52-Week Range $9.30 - 17.55
Shares Outstanding (Mil)46.46

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 232 242 265
EPS ($) 0.93 1.03 1.36
EPS without NRI ($) 0.93 1.03 1.36
EPS Growth Rate
(Future 3Y To 5Y Estimate)
97.00%
Dividends per Share ($)
» More Articles for SCMP

Headlines

Articles On GuruFocus.com
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of America Merrill Lynch 2 May 11 2017 
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank 42nd Annual Healt Apr 26 2017 
Sucampo Announces First Quarter 2017 Earnings Call Apr 19 2017 
New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Diseas Apr 18 2017 
7 of the Worst-Performing Stocks in Gurus' Portfolios Apr 07 2017 
Sucampo Acquires Vtesse Inc. Apr 03 2017 
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 16th Annual Needham Healthcare Mar 28 2017 
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Oppenheimer 27th Annual Healthc Mar 15 2017 
NeoPhotonics Delivers Sustained Profitability; Gevo Continues Biofuel Deal Momentum May 08 2015 
Pharmaceutical Stock Picks For March Mar 04 2015 

More From Other Websites
Edited Transcript of SCMP earnings conference call or presentation 3-May-17 12:30pm GMT May 19 2017
Cerecor Appoints Steven Boyd and Peter Greenleaf to Board of Directors May 15 2017
Sucampo Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SCMP) : May 12, 2017 May 12 2017
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Bank of America Merrill Lynch... May 11 2017
Sucampo Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SCMP-US : May... May 11 2017
Investor Network: Sucampo Pharmaceuticals, Inc. to Host Earnings Call May 03 2017
Sucampo tops 1Q revenue forecasts May 03 2017
Sucampo Reports First Quarter 2017 Financial Results May 03 2017
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Deutsche Bank 42nd Annual... Apr 26 2017
ETFs with exposure to Sucampo Pharmaceuticals, Inc. : April 26, 2017 Apr 26 2017
Sucampo Announces First Quarter 2017 Earnings Call Apr 19 2017
New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick... Apr 18 2017
Sucampo (SCMP) Down 7.6% Since Earnings Report: Can It Rebound? Apr 10 2017
7 of the Worst-Performing Stocks in Gurus' Portfolios Apr 07 2017
Sucampo just bought this local rare disease company for $200M Apr 03 2017
Sucampo Acquires Vtesse Inc. Apr 03 2017
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 16th Annual Needham Healthcare... Mar 28 2017
Local drug company stocks react to Trump's proposed cuts to NIH, FDA Mar 16 2017
Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the Oppenheimer 27th Annual... Mar 15 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)